Cipla's mother-baby pack wins BioSpectrum award

Updated on 11 May 2012

Cipla's Mother-Baby Pack wins BioSpectrum Asia Pacific Product of the Year Award for 2011 for its contribution in fighting HIV/AIDS among pregnant women and bring down transmission

cipla-mother-baby-pack

Mother-baby pack by Cipla

Towards the end of November 2010, Cipla, a Mumbai-based pharmaceutical major, took a step ahead in revolutionizing HIV/AIDS treatment and reducing the incidence of mother-to-child transmission of HIV/AIDS by developing a first-of-its-kind ‘Mother-Baby Pack' in collaboration with UNICEF and other partners. The Mother-Baby Pack contains the entire range of antiretroviral drugs and antibiotics required by an HIV-infected mother starting from the 14th week of her pregnancy until the 6th week after delivery.

Developed in line with the latest World Health Organization (WHO) guidelines on Prevention of Mother-to-Child Transmission (PMTCT), the Mother-Baby Pack is a color-coded take-home kit with simple graphics to help mothers identify the different sets of drugs each to be taken during pregnancy, during labor and breastfeeding, covering the entire period when the transmission can occur. Also, the pack contains drugs for the new born baby.

The product won the BioSpectrum Asia Pacific Bioscience Industry Product of the Year for 2011.

Genesis of the pack

On making a landmark contribution in the fight against HIV/AIDS, Dr Y K Hamied, chairman, Cipla said, "We were approached by UNICEF to produce this pack for the PMTCT program. The specially designed Mother-Baby Pack will increase adherence and play a pivotal role in the total prevention of mother-to-child transmission of HIV/AIDS." The core team involved in the development of this product were Dr Jaideep A Gogtay, medical director, Dr Viraj Mehta , medical services and Mr Prashant Sisodia, regional manager for Africa and Institutional Business.

Informs Sisodia, "The initiative took place two years back and with the launch of this pack, we have entered 10 countries and slowly intend to move to other countries as well."

UNICEF had approached Cipla with this idea keeping the African nations in mind. The pack has already been launched in Kenya, Cameroon, Zambia and Lesotho. Says Dr Gogtay, "The disease is widely prevalent in the Sub-Saharan African countries, especially the mother to child transmission of the disease. So, the UN decided to come up with this pack from an African perspective."

Benefits

With the launch of the Mother-Baby Pack that costs $70 and covers a period of 12 months, now an HIV positive mother-to-be even in the remotest corner of the least developed nations would have daily access to essential PMTCT drugs during her entire term of pregnancy in the convenience of her own home.

Informs Dr Mehta, "The mother-to-child transmission of the virus can happen at three stages - during gestation, labor and delivery or post delivery during breast feeding."

"Basically, we have appropriate intervention designed at preventing transmission at each of these three stages. We have a pictorial and graphically designed booklet, color coding of the boxes within the pack which explains all the steps so that even an illiterate person can understand how to use the pack," adds Dr Mehta. The pack is also available in languages like French because a large majority of the population in West Africa are French-speaking people.

The most important benefit of the Mother-Baby pack, as pointed out by doctors is that it would drastically help in reducing the number of child deaths due to AIDS.

Previous 1

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X